10-Q: Simulations Plus Reports Strong Q2 FY26 Results

Simulations Plus, Inc. announced its second quarter fiscal year 2026 financial results, showcasing significant revenue growth and improved profitability.

Summary

• Total revenues for the three months ended February 28, 2026, increased by 8% to $24.3 million compared to $22.4 million in the prior year period.
• For the six months ended February 28, 2026, total revenues grew 3% to $42.7 million from $41.4 million in the same period last year.
• Net income for the three months ended February 28, 2026, rose by 48% to $4.5 million, or $0.22 per diluted share, compared to $3.1 million, or $0.15 per diluted share, in the prior year.
• For the six months ended February 28, 2026, net income increased by 59% to $5.2 million, or $0.26 per diluted share, compared to $3.3 million, or $0.16 per diluted share, in the prior year.
• Operating cash flow for the six months ended February 28, 2026, was $10.6 million, a significant improvement from $4.4 million in the prior year period.
• The company reported $25.7 million in cash and cash equivalents and $16.1 million in short-term investments as of February 28, 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, with significant improvements in revenue, profitability, and cash flow, indicating robust operational performance and effective cost management.

Positives

• Total revenues increased by 8% to $24.3 million for the three months ended February 28, 2026.
• Services revenue saw a significant increase of 12% to $19.2 million for the six months ended February 28, 2026.
• Gross profit for the three months ended February 28, 2026, increased by 23% to $16.1 million, with an improved gross margin of 66% from 59% in the prior year.
• Gross profit for the six months ended February 28, 2026, increased by 16% to $27.0 million, with an improved gross margin of 63% from 56% in the prior year.
• Income from operations for the three months ended February 28, 2026, more than doubled to $5.6 million, an increase of 108%.
• Income from operations for the six months ended February 28, 2026, increased by 124% to $6.3 million.
• Net income for the three months ended February 28, 2026, increased by 48% to $4.5 million.
• Net income for the six months ended February 28, 2026, increased by 59% to $5.2 million.
• Operating cash flow improved significantly, from $4.4 million to $10.6 million for the six months ended February 28, 2026.
• The company has a strong liquidity position with $25.7 million in cash and cash equivalents and $16.1 million in short-term investments as of February 28, 2026.

Negatives

• Software revenue decreased by 3% to $23.5 million for the six months ended February 28, 2026, compared to the prior year period.
• Clinical Operations solutions revenue declined by $1.9 million for the six months ended February 28, 2026.
• The effective tax rate increased to 23% for the three months and 24% for the six months ended February 28, 2026, compared to 12% and 13% respectively in the prior year, due to a favorable discrete item in the prior year not recurring and less favorable jurisdictional mix of earnings.
• Accounts receivable increased significantly from $9.7 million to $18.2 million, potentially indicating longer collection cycles or increased sales.

Risks

• The company faces risks related to global drug pricing, which could lead to temporary reductions in R&D spending by pharmaceutical and biotech companies.
• The biopharma industry is highly competitive and changes rapidly, requiring continuous product development and new distribution channels.
• Risks associated with the establishment of technological feasibility and recoverability of capitalized software development costs.
• Potential for impairment of intangible assets and goodwill if events or circumstances indicate that carrying amounts may not be recoverable.
• Concentration of credit risk due to cash balances exceeding FDIC-insured limits and deposits held in a bank in France that is not FDIC-insured.
• Revenue concentration from international sales (30% for the six months ended February 28, 2026) and from the three largest customers (9%, 5%, and 3% of total revenues for the six months ended February 28, 2026).

Future Outlook

The company expects existing cash, cash equivalents, short-term investments, and cash generated from ongoing operations to be sufficient to fund its operating activities and cash commitments for the next 12 months. The company continues to seek opportunities for strategic acquisitions, investments, and partnerships, which may require a substantial portion of its cash reserves or consideration of financing options.

Management Comments

• Our MIDD software and services allow clients to use modeling and simulation to accelerate drug development, reduce the costs of R&D, comply with regulatory guidance and best practices, and increase confidence in the safety and efficacy of their drugs and biologics.
• Our adaptive learning solutions support the success of clinical trials by accelerating recruitment of an appropriate patient population, increasing retention of participants, and by driving competency and compliance with trial protocols, while our medical communications solutions provide support in obtaining regulatory approval and commercialization of drugs.
• The Company is headquartered in Research Triangle Park, North Carolina, and has a European office in Paris, France. The Company has a remote work culture that supports employee work-life balance and minimizes its carbon footprint.

Industry Context

StockSavvy.ai notes that Simulations Plus's performance reflects a growing demand for advanced modeling and simulation tools in the biopharma sector, driven by the increasing complexity and cost of drug development. The company's focus on integrating AI and cloud-based solutions positions it to capitalize on industry trends towards digital transformation and efficiency.

Comparison to Industry Standards

• The company's gross margin for software (89% for Q2 FY26) is generally higher than typical software industry averages, reflecting the specialized nature of its products.
• The services gross margin (33% for Q2 FY26) is in line with many professional services firms, but the improvement indicates increasing efficiency.
• The R&D spend as a percentage of revenue (14% for Q2 FY26) is consistent with or slightly higher than many technology companies investing in innovation, particularly in specialized scientific software markets.
• The company's revenue growth of 8% for the quarter is solid, especially considering the challenging macroeconomic environment and the long development cycles in the biopharma industry, which can lead to fluctuating R&D spending by clients.

Management Changes

Legal Proceedings

• The company is not a party to any legal proceedings and is not aware of any pending or threatened legal proceedings of any kind.

Stakeholder Impact

• Shareholders: Positive impact due to increased net income, EPS, and improved financial health, potentially leading to stock price appreciation.
• Employees: Continued investment in R&D and a remote work culture may benefit employees. Headcount reductions in certain areas could impact those affected.
• Customers: Continued development of advanced software and consulting services supports clients in accelerating drug development and reducing costs.
• Creditors: Improved financial performance and strong liquidity position are positive for creditors.

Next Steps

• Continue investment in innovation for future growth, including the development of an integrated, cloud-enabled modeling ecosystem.
• Seek opportunities for strategic acquisitions, investments, and partnerships.
• Monitor and manage R&D spending, balancing investment in innovation with operational efficiency.
• Continue to optimize real estate footprint consistent with a remote-first operating model.

Key Dates

Recommendation

The company has demonstrated strong operational improvements and financial performance, with significant growth in revenue and profitability. However, the increase in R&D spending, potential for future strategic acquisitions requiring capital, and the inherent cyclicality of R&D budgets in the biopharma sector warrant a cautious approach. While the results are better than expected, the current valuation and future growth drivers should be closely monitored. A 'hold' recommendation allows investors to assess the sustainability of these improvements and the impact of ongoing strategic initiatives.

Keywords

Simulations Plus, 10-Q, SEC Filing, Financial Results, Software, Services, Biopharma, Drug Development, Modeling and Simulation, Revenue Growth, Net Income, Earnings Per Share, Cash Flow